Check out the latest Prokaryotics buzz below.


Prokaryotics Advances Its Third SBIR-funded Antibiotic Research Program into Phase 2

Union, NJ -- August 16, 2021 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has successfully advanced its third Small Business Innovation Research (SBIR R44AI145409-02) grant into Phase 2, a two year award valued at nearly $2 million dollars. Please click here for more details.


Prokaryotics receives Notice of Allowance from U.S. Patent and Trademark Office for two patents covering novel compounds which restore the efficacy of commonly used β-lactams against MRSA

Union, NJ -- June 9, 2021 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has received a Notice of Allowance for two patents, each covering a distinct series of novel compounds for both composition of matter and use as adjuvants to restore the efficacy of commonly used β-lactams against the dangerous superbug MRSA. Please click here for more details.


AiCuris selects Prokaryotics Inc. in its inaugural AiCubator Initiative to support Innovation in Infectious Disease

Union, NJ -- January 13, 2021 -- Prokaryotics Inc. announces that its bacterial cell envelope-targeting antibiotic program has been recognized by AiCuris as a novel and scientifically attractive resistance breaking opportunity of high priority. Please click here for more details.


Prokaryotics Receives $385,000 R21 NIH Grant Supporting A Fourth Novel Antibiotic Program

Union, NJ -- August 19, 2020 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded an R21 grant valued at up to $385,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


NJEDA Commission on Science, Innovation and Technology Announces Recipients of New Jersey SBIR/STTR Funding Support. Prokaryotics is proud to be among the 14 early stage innovation companies to receive this award.

Union, NJ -- June 18, 2020 -- Prokaryotics Inc, a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been selected as one of fourteen life sciences companies in the Garden State to receive funding support by the New Jersey Commission on Science, Innovation and Technology. Please click here for more details.


Prokaryotics Receives $2.3 Million SBIR Award Supporting Its Immune Potentiation Program and Advances Two Additional SBIR-funded Antibiotic Programs into Phase 2 Lead Optimization

Union, NJ -- August 1, 2019 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its third Small Business Innovation Research (SBIR) grant valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


New Hackensack Meridian Health- Center for Discovery and Innovation to receive $33.3 million grant from the NIH to develop a Center of Excellence for antibiotic discovery

Nutley, N.J -- May 10, 2019 -- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has selected infectious disease expert David S. Perlin, Ph.D. and Chief Scientific Officer of the new Hackensack Meridian Health-Center for Discovery and Innovation (CDI) to lead a major research effort aimed at developing novel antibiotics to overcome deadly bacteria in hospitals that have become resistant to current treatments. This grant reflects the core mission of the CDI to rapidly translate scientific innovations to address critical unmet clinical needs. Please click here for more details.


Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds

Union, NJ -- April 14, 2019 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia. Please click here for more details.


Prokaryotics Receives $2.3 Million SBIR Grant Supporting A Second Novel Antibiotic Program

Union, NJ -- September 13, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its second Small Business Innovation Research Grant (SBIR) valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


Prokaryotics Receives $2.5 Million SBIR Grant to Support Novel Antibiotic Program

Union, NJ -- March 08, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded a Small Business Innovation Grant (SBIR) valued at up to $2.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


Media Coverage

Union, NJ -- January 30, 2018 -- We appreciate Merck's support and, with our collaborators, are committed to taking on the global challenge of antibiotic resistance. Please click the link for details. Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D.


Prokaryotics Announces Licensing Agreement with Merck

Union, NJ -- January 25, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Merck, known as MSD outside the United States and Canada. Please click here for more details.


Novel Antibiotic Discovery Startup Commences Operations

Union, NJ -- January, 2017 -- Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs.